title: [Introductory clinical evaluation of fluticasone propionate efficacy for treatment of allergic rhinitis in children].
abstract: The investigations were carried out on 13 children with seasonal rhinitis, and in 10 children with perennial rhinitis. The fluticasone propionate (Flixonase-Glaxo) was introduced in acute state of disease: one dose to each nostril (100 micrograms) for the patient 7-11 years old, and in the patients under 11 years old--two doses to each nostril (200 micrograms) in the morning, during 3 weeks. The clinical effects were established using score-system in 0-3 points scale which included essential symptoms like: itching, sneezing, nasal blockade, rhinorrhoea, mucosal oedema and eyes irritation. Very good and good effects of the treatment in patients with seasonal rhinitis in 93% of children was observed. In the group of patients with perennial rhinitis, very good and good results, was observed in 80% of children. Easy dosage, high efficacy, very nice smell and no side-effects make this medicine very usefull in the treatment of allergic rhinitis in children.
authors.affiliation: Zakład Alergologii Dzieciecej Akademii Medycznej w Bialymstoku.
authors.forename: J
authors.initials: J
authors.lastname: Hofman
authors.forename: A
authors.initials: A
authors.lastname: Trofimowicz
mesh_terms: D000293:Adolescent; D000730:Androstadienes / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D002648:Child; D005260:Female; D000068298:Fluticasone; D006801:Humans; D008297:Male; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D000068298:Fluticasone